Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.

Viruses - 16 Jun 2021

Minosse Claudia, Gruber Cesare E M, Rueca Martina, Taibi Chiara, Zaccarelli Mauro, Grilli Elisabetta, Montalbano Marzia, Capobianchi Maria R, Antinori Andrea, D'Offizi Gianpiero, McPhee Fiona, Garbuglia Anna Rosa

Abstract excerpt

The risk of hepatitis C virus (HCV) recurrence after direct-acting antiviral (DAA) treatment is <0.5%. However, the distinction between HCV RNA late relapse and reinfection still represents a challenge in virological diagnostics. The aim of this study was to employ next-generation sequencing (NGS) to investigate HCV RNA recurrence in patients achieving a sustained virologic response (SVR) at least six months...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Hepacivirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to High-Throughput Nucleotide Sequencing

Share to Phylogeny

Share to Recurrence

Share to RNA, Viral

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34208646
DOI: 10.3390/v13061151
PMCID: PMC8235384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Late Relapse and Reinfection in HCV Patients Treated with Direct-Acting Antiviral (DAA) Drugs.PMID 34208646Read ↗

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies.Semantic proximity Read ↗

Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.Semantic proximity Read ↗

HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals.Semantic proximity Read ↗

Viral kinetics during the first weeks of pegylated interferon and ribavirin treatment can identify patients at risk of relapse after its discontinuation: new strategies for such patients?Semantic proximity Read ↗

Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.Semantic proximity Read ↗

The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C-infected patients treated with direct-acting antivirals with and without pegylated interferon: A Belgian experience.Semantic proximity Read ↗

Evolution of the NS3 and NS5B regions of the hepatitis C virus during disease recurrence after liver transplantation.Semantic proximity Read ↗

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study.Semantic proximity Read ↗

Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection?Semantic proximity Read ↗

Relapse to prior therapy is the most important factor for the retreatment response in patients with chronic hepatitis C virus infection.Semantic proximity Read ↗

An inadequate dose of ribavirin is related to virological relapse by chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin.Semantic proximity Read ↗

Dynamic changes of HCV genomes under selective pressure from DAAs therapy in relapsed patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.